Absci Stock
Absci Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sean McClain
- Employees
- 140
- Market cap
- $1.4 B
- IPO
- 22/07/2021
Absci Corporation is a biopharmaceutical company in the Healthcare sector, operating within the Biotechnology industry. Based in Vancouver, Washington, the firm focuses primarily on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Absci stock: price history
1D
-7.1%
1W
-18.8%
1M
+2.6%
6M
+130.4%
YTD
+136.4%
1Y
+69.4%
2Y
+99.8%
5Y
-22.4%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~8% stronger price swings than usual
Absci stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
1 more assignment (Enabler/Second row) Pro-only.
Absci Corporation is a biopharmaceutical company that combines the phases of drug discovery and cell line engineering through an integrated platform. The company develops biological therapeutics and essential cell lines for manufacturing, making these available to its partners. Through this technologically optimized process, Absci enables more efficient development of biologics.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Absci
Analyst assessment of Absci
PRICE TARGET LOW
US$10.00
CONSENSUS
US$13.60
MEDIAN
US$15.00
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
11
BUY
1
HOLD
1
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 12/10/2026
Absci stock metrics
P/E
-10.31
P/B
5.28
EV/EBITDA
-11.93
RETURN ON EQUITY
-13.5%
NET MARGIN
-10,443.4%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.3%
FLOAT SHARES
148,102,882
AVG. DAILY VOLUME (30D)
4,060,238
Insider transactions (SEC)
McClain Sean
Bedrick Todd
Jonasson Zachariah
Jonasson Zachariah
Szela Mary T
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Absci stock
What does Absci do?
Absci Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sean McClain, the company employs around 140 people.
The IPO was on 22/07/2021; the stock trades on NASDAQ under the ticker ABSI.
What do analysts say about Absci stock?
13 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$13.60, ranging from US$10.00 to US$16.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Absci report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Absci pay a dividend?
No, Absci currently does not pay a dividend.
Which stocks are comparable to Absci?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Absci stock analyzed?
Clicking "Analyze stock" lets five strategies assess Absci against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.